Tiziana $TLSA: Analyst Anticipates Promising Developments in Foralumab Trials for SPMS & Alzheimer's
Benzinga
Benzinga
  • 7 months ago
Tiziana Life Sciences (NASDAQ: TLSA) is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis (SPMS), Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Crohn's disease and more.
Recommended
1:52
I
Up next
Clinical trials into heart diseases begin in Melbourne's west
ABC NEWS (Australia)
0:34
Full version Essentials of Clinical Infectious Diseases For Kindle
yahoni3522
0:10
Best seller Radiation Therapy of Benign Diseases: A Clinical Guide (Medical Radiology/Radiation
coltosukka
0:35
Dermatopathology of Tropical Diseases: Pathology and Clinical Correlations
tekam
Benzinga
0:40
Maryland Teacher Faces Criminal Charges for Spreading an AI-Generated Fake Recording of the Principal Making Racist Comments
Benzinga
0:27
Arizona Grand Jury Indicts 18 Individuals Involved in Submitting Fake Elector Documents
Benzinga
0:46
ByteDance Unlikely to Sell TikTok, Preferring Shutdown in the US to Parting Ways with Its Key Algorithm
Benzinga
0:35
Google Parent Alphabet Announces $70 Billion Stock Buyback Program After Stellar Q1 Results
Benzinga
0:38
Analysts Predict Chevron and ExxonMobil Will Report Lower Q1 Profits Despite Rising Oil Prices
Benzinga
0:39
Meta Stock Plummets 15% as Market Reacts to Increased AI Spending
Benzinga
Featured channels
More from
EarthX
More from
TIME
More from
Insider
More from
What's Trending
More from
Entrepreneur
More from
SportsGrid